Phathom Pharmaceuticals (PHAT) Stock: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$5.21
-1.80 (-25.68%)
▼
5d:
-24.71%
30d:
-26.41%
90d:
-56.4%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Oct 29, 2026
5d
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PHAT is down 24.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PHAT is down 24.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.13
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.29
17.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $5.21, which is considered oversold relative to its 30-day fair value range of $6.73 to $7.73. The stock's valuation (Forward PE: 7.3) is in line with its historical norms (7.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAT is in a strong downtrend. The price is currently testing key support at $6.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 25.7% recently.
Market Sentiment: PHAT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.64 (+180.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAT is in a strong downtrend. The price is currently testing key support at $6.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 25.7% recently.
Market Sentiment: PHAT scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.64 (+180.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.73 -
$7.73
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding PHAT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-25.7%)
- BULLISH: Trading 180.1% below Wall St target ($19.64)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.73 -
$7.73
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.78
Resistance Level
$7.72
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.27
Wall Street Target
$19.64
(+180.1%)
Revenue Growth (YoY)
88.0%
Profit Margin
-41.3%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
7.3 vs 7.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$6.94
(-1%)
2-Year Target
$6.87
(-2%)
3-Year Target
$6.80
(-3%)
3-Yr Target (if PE normalizes)
(PE: 7→8)
$7.01
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.3 to 7.5
Stabilization Target:
$7.23
(+3.1%)
PE Expansion Potential:
+3.1%
Share & Embed Analysis
Last updated: October 23, 2026 12:16 PM ET
Data refreshes hourly during market hours. Next update: 1:16 PM
Data refreshes hourly during market hours. Next update: 1:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 63 BUY |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 63 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
